Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Trading Up 0.7% – What’s Next?

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP)’s stock price rose 0.7% during trading on Monday . The stock traded as high as $5.84 and last traded at $5.76. Approximately 37,477 shares traded hands during trading, a decline of 93% from the average daily volume of 569,795 shares. The stock had previously closed at $5.72.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price target on Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, February 4th.

Neuphoria Therapeutics Inc. – Common Stock Stock Up 1.8 %

The business’s 50 day simple moving average is $5.04.

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) last released its quarterly earnings data on Friday, February 14th. The company reported ($1.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.01) by $0.78. The firm had revenue of $660 billion during the quarter. On average, sell-side analysts expect that Neuphoria Therapeutics Inc. – Common Stock will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Neuphoria Therapeutics Inc. – Common Stock

An institutional investor recently bought a new position in Neuphoria Therapeutics Inc. – Common Stock stock. Lynx1 Capital Management LP bought a new stake in Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 45,806 shares of the company’s stock, valued at approximately $157,000. Neuphoria Therapeutics Inc. – Common Stock accounts for about 0.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned 2.81% of Neuphoria Therapeutics Inc. – Common Stock at the end of the most recent quarter. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Neuphoria Therapeutics Inc. – Common Stock

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.